117 results about "Thromboembolic disease" patented technology

The present invention is generally related to the discovery of the therapeutic benefit of administering gamma-tocopherol and gamma-tocopherol derivatives. More specifically, the use of gamma-tocopherol and racemic LLU-alpha, (S)-LLU-alpha, or gamma-tocopherol derivatives as antioxidants and nitrogen oxide scavengers which treat and prevent high blood pressure, thromboembolic disease, cardiovascular disease, cancer, natriuretic disease, the formation of neuropathological lesions, and a reduced immune system response are disclosed.

A dynamic device for reducing functional mitral regurgitation is described. The device is disposed externally to the heart and effectively acts as a splint for reducing further dilation of the heart in patients diagnosed with cardiomyopathy, and for reducing tethering of the papillary muscle on the mitral valve. The device does not require cardiopulmonary bypass for its installation since it is attached to the outside of the left ventricle, thereby reducing surgical risk, and is not exposed to the patient's blood once installed, thereby reducing the risk of thromboembolic disease.

A device for transdermally delivering an anticoagulant agent by electrotransport. Preferably, the anticoagulant comprises a benzamidine or a naphthamidine derivative. A particularly preferred benzamidine derivative is a 2-[3-[4-(4-piperidinyloxy) anilino]-1-propenyl]benzamidine derivative. The devices are configured to maintain a plasma concentration of 20-80 ng / mL or providing a flux in the range of approximately 20 - 40 mg / day. Suitable current densities include 0.050 and 0.10 mA / cm<2>. Methods of the invention include delivering the anticoagulants to precisely maintain the desired plasma concentrations. The invention also comprises treating thromboembolic disease and inhibiting Factor Xa.

The present invention relates to compounds of the formula I,whereinR1; R2; Z; A; B; D; Q; J; V; G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong anti-aggregating effect on platelets and thus an anti-thrombotic effect and are suitable, e.g., for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible antagonists of the platelet ADP receptor P2Y12, and can in general be applied in conditions in which an undesired activation of the platelet ADP receptor P2Y12 is present or for the cure or prevention of which an inhibition of the platelet ADP receptor P2Y12 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

The present invention relates to compounds of the formula I,whereinR1; R2; Z; A; B; D; Q; J; V; G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong anti-aggregating effect on platelets and thus an anti-thrombotic effect and are suitable, e.g., for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible antagonists of the platelet ADP receptor P2Y12, and can in general be applied in conditions in which an undesired activation of the platelet ADP receptor P2Y12 is present or for the cure or prevention of which an inhibition of the platelet ADP receptor P2Y12 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

The present invention relates to isolated 18-mer peptides corresponding to amino acid residues 369-386 of human plasminogen activator inhibitor 1 (PAI-1) and fragments thereof, compositions that include such peptides, and uses of such compositions for treating thromboembolic diseases and pathological conditions associated with neurological damage.

The present invention discloses the use of sea cucumber glycosaminoglycan in preparing medicine; animal testing has shown that for a weight average molecular weight exceeding 54,500Da of depolymerized sea cucumber glycosaminoglycan or of one or more segments of natural molecular segments of sea cucumber glucosaminoglycan, the anti-coagulant activity thereof shows dose-dependency; in contrast to heparin and low molecular weight heparin, the dose-dependency thereof increases the incremental easing of blood coagulation, and, with an identical dose size, as weight average molecular weight increases, the onset time is delayed while the duration of efficacy is increased. For certain dosages, natural molecular segment sea cucumber glycosaminoglycan can have a duration of efficacy of up to 16 hours, and can be used for preparing medicine for preventing and treating arterial thromboembolic diseases. The present invention has a higher level of safety when compared with heparin-type drugs and vitamin K antagonist-type drugs. In clinical use, the present invention has a wide treatment window for thromboembolic disease, has a high level of safety, and has good research and development value.